As clinicians, we know that lowering low-density lipoprotein cholesterol (LDL-C) with statins alone or in combination with nonstatin therapies such as a proprotein convertase subtilisin/kexin type 9 ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...
A new study led by Baylor College of Medicine and presented at the American College of Cardiology’s Annual Scientific Session together with World Congress of Cardiology found that an oral PCSK9 ...
In a recent study published in PNAS, researchers from the University of Texas Southwestern Medical Center investigated cholesterol-mimetic compounds specifically binding and inhibiting Scap. Their ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...
Having high blood cholesterol levels (hypercholesterolemia) is a risk factor for heart diseases like heart attacks and strokes because it can lead to plaque buildup, which can restrict blood flow. For ...
Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice. Like all cancers, bladder ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A once-daily oral PCSK9 inhibitor reduced LDL in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results